{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:22:16Z","timestamp":1772857336996,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Emerg Hosp Med Rep"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40138-014-0040-z","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T05:38:24Z","timestamp":1393306704000},"page":"126-132","source":"Crossref","is-referenced-by-count":22,"title":["Vasodilators in Acute Heart Failure: Review of the Latest Studies"],"prefix":"10.1007","volume":"2","author":[{"given":"Phillip D.","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"40_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389\u201393. Early paper describing the effects of high-dose nitrates in acute heart failure.","DOI":"10.1016\/S0140-6736(97)08417-1"},{"key":"40_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50:144\u201352. First paper to report the effects of high-dose nitroglycerin in acute heart failure.","DOI":"10.1016\/j.annemergmed.2007.02.022"},{"key":"40_CR3","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.1073\/pnas.132271799","volume":"99","author":"LJ Ignarro","year":"2002","unstructured":"Ignarro LJ. After 130\u00a0years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci USA. 2002;99:7816\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"key":"40_CR4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/BF00874655","volume":"18","author":"PR Imhof","year":"1980","unstructured":"Imhof PR, Ott B, Frankhauser P, et al. Difference in nitroglycerin dose-response in the venous and arterial beds. Eur J Clin Pharmacol. 1980;18:455\u201360.","journal-title":"Eur J Clin Pharmacol"},{"key":"40_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0735-1097(93)90841-N","volume":"22","author":"HL Haber","year":"1993","unstructured":"Haber HL, Simek CL, Bergin JD, et al. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol. 1993;22:251\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"40_CR6","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 S Munir, A Guilcher, T Kamalesh, et al. Peripheral augmentation index defines the relationship between central and peripheral pulse pressure. Hypertension. 2008;51:112\u20138. Succintly explains the key points in understanding the relationship between central and peripheral blood pressure.","DOI":"10.1161\/HYPERTENSIONAHA.107.096016"},{"key":"40_CR7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3810\/hp.2011.02.382","volume":"39","author":"EF Aziz","year":"2011","unstructured":"Aziz EF, Kukin M, Javed F, et al. Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure. Hosp Pract (Minneap). 2011;39:126\u201332.","journal-title":"Hosp Pract (Minneap)."},{"key":"40_CR8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32\u201343.","journal-title":"N Engl J Med"},{"key":"40_CR9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","volume":"14","author":"SL Teichman","year":"2009","unstructured":"Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321\u20139.","journal-title":"Heart Fail Rev"},{"key":"40_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","volume":"373","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429\u201339.","journal-title":"Lancet"},{"key":"40_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29\u201339. Pivotal paper describing the beneficial effects of serelaxin, a novel therapeutic for acute heart failure, as found in a relatively large randomized trial.","DOI":"10.1016\/S0140-6736(12)61855-8"},{"key":"40_CR12","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/eurheartj\/eht371","volume":"34","author":"M Metra","year":"2013","unstructured":"Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J. 2013;34:3128\u201336.","journal-title":"Eur Heart J"},{"key":"40_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196\u2013206. Important paper that shows the potential benefits of serelaxin may lie in organ protection.","DOI":"10.1016\/j.jacc.2012.11.005"},{"key":"40_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0140-6736(12)61896-0","volume":"381","author":"MA Konstam","year":"2013","unstructured":"Konstam MA. RELAX-AHF: rising from the doldrums in acute heart failure. Lancet. 2013;381:5\u20136.","journal-title":"Lancet"},{"key":"40_CR15","doi-asserted-by":"crossref","first-page":"R684","DOI":"10.1152\/ajpcell.1999.276.3.C684","volume":"276","author":"MH Bestle","year":"1999","unstructured":"Bestle MH, Olsen NV, Christensen P, et al. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol. 1999;276:R684\u201395.","journal-title":"Am J Physiol"},{"key":"40_CR16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.ATV.zhq0504.7914","volume":"24","author":"M Schmitt","year":"2004","unstructured":"Schmitt M, Gunaruwan P, Payne N, et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol. 2004;24:911\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"40_CR17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ahj.2005.01.022","volume":"150","author":"V Mitrovic","year":"2005","unstructured":"Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.","journal-title":"Am Heart J"},{"key":"40_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Mitrovic V, Seferovic PM, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823\u201332. Initial paper describing the clinical effects of ularitide.","DOI":"10.1093\/eurheartj\/ehl337"},{"key":"40_CR19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","volume":"52","author":"O Lisy","year":"2008","unstructured":"Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"40_CR20","doi-asserted-by":"crossref","first-page":"e52422","DOI":"10.1371\/journal.pone.0052422","volume":"7","author":"FL Martin","year":"2012","unstructured":"Martin FL, Sangaralingham SJ, Huntley BK, et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012;7:e52422.","journal-title":"PLoS One"},{"key":"40_CR21","doi-asserted-by":"crossref","first-page":"E1037","DOI":"10.1016\/S0735-1097(12)61038-9","volume":"59","author":"J Neutel","year":"2012","unstructured":"Neutel J, Rolston W, Maddock S, et al. Initial experience with subcutaneous infusion of cenderitide in patients with chronic heart failure. J Am Coll Cardiol. 2012;59:E1037.","journal-title":"J Am Coll Cardiol"},{"key":"40_CR22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1751-7133.2009.00133.x","volume":"16","author":"F Peacock","year":"2010","unstructured":"Peacock F, Varon J, Ebrahimi R, et al. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis. Congest Heart Fail. 2010;16:55\u20139.","journal-title":"Congest Heart Fail."},{"key":"40_CR23","first-page":"A15606","volume":"126","author":"WF Peacock","year":"2012","unstructured":"Peacock WF, Chandra A, Collins S, et al. Clevidipine improves dyspnea in emergency department acute heart failure: a randomized, Open Label Study. Circulation. 2012;126:A15606.","journal-title":"Circulation."},{"key":"40_CR24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCHEARTFAILURE.111.962571","volume":"4","author":"G Boerrigter","year":"2011","unstructured":"Boerrigter G, Lark MW, Whalen EJ, et al. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail. 2011;4:770\u20138.","journal-title":"Circ Heart Fail."},{"key":"40_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Boerrigter G, Soergel DG, Violin JD, et al. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012;5:627\u201334. Initial paper describing the clinical effects of biased ligand therapy for acute heart failure.","DOI":"10.1161\/CIRCHEARTFAILURE.112.969220"},{"key":"40_CR26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FJC.0b013e3181b76730","volume":"54","author":"Y Minami","year":"2009","unstructured":"Minami Y, Nagashima M, Kajimoto K, et al. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol. 2009;54:335\u201340.","journal-title":"J Cardiovasc Pharmacol"},{"key":"40_CR27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-8703(97)70078-4","volume":"134","author":"AI Larsen","year":"1997","unstructured":"Larsen AI, Goransson L, Aarsland T, et al. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997;134:435\u201341.","journal-title":"Am Heart J"},{"key":"40_CR28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0002-8703(94)90555-X","volume":"127","author":"T Tsutamoto","year":"1994","unstructured":"Tsutamoto T, Kinoshita M, Nakae I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J. 1994;127:866\u201373.","journal-title":"Am Heart J"},{"key":"40_CR29","doi-asserted-by":"crossref","first-page":"44J","DOI":"10.1016\/0002-9149(89)90204-X","volume":"63","author":"AC Solal","year":"1989","unstructured":"Solal AC, Jaeger P, Bouthier J, et al. Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol. 1989;63:44J\u20138J.","journal-title":"Am J Cardiol"},{"key":"40_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Shirakabe A, Hata N, Yokoyama S, et al. Efficacy and safety of nicorandil therapy in patients with acute heart failure. J Cardiol. 2010;56:339\u201347. Best of the nicorandil studies to be published showing the potential utility in acute heart failure.","DOI":"10.1016\/j.jjcc.2010.07.007"},{"key":"40_CR31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1253\/circj.CJ-11-1110","volume":"76","author":"S Ishihara","year":"2012","unstructured":"Ishihara S, Koga T, Kaseda S, et al. Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circ J. 2012;76:1169\u201376.","journal-title":"Circ J"},{"key":"40_CR32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","volume":"18","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18:123\u201334.","journal-title":"Heart Fail Rev"},{"key":"40_CR33","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","volume":"119","author":"H Lapp","year":"2009","unstructured":"Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119:2781\u20138.","journal-title":"Circulation"},{"key":"40_CR34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","volume":"14","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14:1056\u201366.","journal-title":"Eur J Heart Fail"},{"key":"40_CR35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","volume":"34","author":"E Erdmann","year":"2013","unstructured":"Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34:57\u201367.","journal-title":"Eur Heart J"},{"key":"40_CR36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCHEARTFAILURE.113.000632","volume":"6","author":"HN Sabbah","year":"2013","unstructured":"Sabbah HN, Tocchetti CG, Wang M, et al. Nitroxyl (HNO) a novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013;6:1250\u20138.","journal-title":"Circ Heart Fail."}],"container-title":["Current Emergency and Hospital Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40138-014-0040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40138-014-0040-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40138-014-0040-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:21:10Z","timestamp":1565205670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40138-014-0040-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1007\/s40138-014-0040-z","relation":{},"ISSN":["2167-4884"],"issn-type":[{"value":"2167-4884","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}